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INTRODUCTION
An effective microporous hollow fiber oxygenator
has been developed for cardiopulmonary bypass
procedures ; however, since 1970, no improvements
have been made for an effective extracorporeal mem-
brane oxygenation (ECMO) system (1). The Kolobow
spiral coil membrane oxygenator (Medtronic Inc.,
Anaheim, CA, U.S.A.) was developed in 1972 (2)
and is the only practical available ECMO system in
the United States. This oxygenator is an old-fashioned
device that is inefficient and difficult to handle.
To solve this problem, our laboratory is develop-
ing a new oxygenator using ultrathin silicone rub-
ber hollow fibers (3-7). These devices have dem-
onstrated better biocompatibility and higher gas
transfer performances over and above the already
existing ECMO oxygenator (6, 7). For further high
performance and antithrombogenicity, an oxygenator
with an improved blood flow distributor was fabri-
cated and evaluated with in vitro (8) and short term
ex vivo (9) testing. The purpose of this study was
to evaluate its clinical long-term feasibility for ECMO
using an animal model.
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METHODS
Animal preparation
The animal involved in this study received hu-
mane care in compliance with the “Guiding Princi-
ples in the Case and Use of Animals” approved by the
Council of the American Physiological Society (re-
vised 1980) and the “Guide for the Care and Use of
Laboratory Animals” published by the National In-
stitutes of Health (NIH Publication No. 85-23, re-
vised 1985). A healthy miniature female calf (Dex-
ter strain) weighing 90 kg and 11 months old was
the subject of this study. A calf of this age was es-
sential for this study because an animal with normal
physiological adult circulation was needed, without
abnormal anatomy due to the fetal circulation (i.e.
atrial septal defect). Complete blood cell count (CBC),
blood biochemistry, and plasma free hemoglobin
were examined before surgery.
Surgical procedure
Anesthesia was induced using 4% halothane with
50% nitrous oxide through a special mask. When
the animal was anesthetized, endotracheal intubation
was performed and anesthesia was maintained by
1-2% halothane with 100% oxygen. A 15 cm longitu-
dinal incision was made along the jugular vein on
the left side of the neck, and the left carotid artery
and jugular vein were dissected. The arterial can-
nula was inserted through a small arteriotomy and
threaded proximally into the artery ; the venous
cannula was inserted through the jugular vein in the
proximal direction in the same manner. After placing
the arterial and venous cannulae, both were exter-
nalized and connected to the extracorporeal circuit,
and the pump circuit was activated. The Gyro C1E3
(Kyocera Corporation, Kyoto, Japan) was used for
the centrifugal pump. Mean arterial pressures were
maintained at more than 80 mmHg. Activated clotting
time (ACT) was maintained at approximately 400
sec throughout the experiment using heparin. When
the calf completely recovered from the anesthesia,
the ECMO study was started. At the end of experi-
ment, euthanasia and necropsy were performed.
Membrane Oxygenator
A new silicone hollow fiber membrane oxygenator
(Preproduction model PPM-04, Fuji Systems Inc.,
Tokyo, Japan) was fabricated for long-term ECMO
application based on the results of a previous mod-
el (PPM-03) (8, 9). The major changes in the new
improved model (PPM-04) are an increase in the
fiber length (from 100 to 150 mm) and the surface
area (from 0.8 to 1.0 m2) to increase the gas trans-
fer rate, a decrease in the packing density (from
45 to 40%) to decrease the pressure drop, and a
specially-designed blood flow distributor (from 4
chambers to 1 chamber) incorporated into the cen-
ter of the module to prevent blood stagnation. Con-
sequently, the new ECMO oxygenator module was
220 mm long and contained in a silicone coated
acrylic housing. The priming volume of this module
was 200 ml. This oxygenator was of the extracapillary
flow type, in which blood flows outside the hollow
fibers (Fig. 1).
Measurements
Gas transfer rate : At a blood flow rate of 1 L/min
and V/Q=3 (V=gas flow rate ; Q=blood flow rate),
the O2 and CO2 gas transfer rates were evaluated
for 2 weeks (ECMO condition). Blood gas samples,
taken from the inlet and outlet sampling ports, were
analyzed every day using a System 1306 pH/blood gas
analyzer (Instrumentation Laboratories, Lexington,
MA, U.S.A.). Three samples were measured for each
sampling time. The O2 content and O2 transfer rate
and the CO2 content and transfer rates were cal-
culated by the following standard formulas :
O2 content (Vol%)=(Hb×1.34×%O2 saturation)/
100+PO2×0.003
Fig. 1. A photograph shows the new hollow fiber silicone
membrane oxygenator.
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O2 transfer rate (ml/min)=(CaO2 - CvO2)×blood
flow rate
Total CO2 (mmol/L)=HCO3-+0.03×PCO2
CO2 transfer rate (ml/min)=22.4×(tCO2v - tCO2a)×
blood flow rate
where Hb is hemoglobin (g/dl), PO2 is oxygen par-
tial pressure (mmHg), CaO2 is arterial oxygen con-
tent (Vol%), CvO2 is venous oxygen content (Vol%),
the blood flow rate represents pump flow rate (L/min),
HCO3 - is plasma bicarbonate ion concentration
(mmol/L), PCO2 is CO2 partial pressure (mmHg),
tCO2v is venous total CO2 (mmol/L), and tCO2a is
arterial total CO2 (mmol/L).
Hemolysis test : Plasma free hemoglobin was
measured every day. The method of measuring
plasma free hemoglobin has been described by
Mizuguchi et al . (10).
Pressure drop measurement : Pressure differences
between the inflow and outflow ports were monitored
to assess the pressure drop in the oxygenator through-
out the experiment using a pressure monitor (Living
Systems Instrumentation, Burlington, VT, U.S.A.).
CBC and biochemistry study : CBC, lactate
dehydrogenase (LDH), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), blood urea
nitrogen (BUN), creatinine, total billirubin (T. Bil),
total protein (TP), and electrolytes (Na, K, Cl) were
measured every two days postoperatively.
RESULTS
A 2-week ex vivo experiment was successfully per-
formed without exchanging the oxygenator. The
stable and reliable performance of this new oxygenator
was demonstrated for the entire experiment.
Gas Transfer Performance : Fig. 2 shows the re-
sults of gas exchange performance tests. The O2
and CO2 gas transfer rates at a blood flow rate of
1 L/min and V/Q=3 were maintained at 41.72±4.13
(mean±SD) ml/min and 40.97±14.49 ml/min, re-
spectively, for 2 weeks.
Hemolysis test : As shown in Fig. 3, the plasma
free hemoglobin was maintained at 5.50±2.20 mg/
dl for 2 weeks.
Pressure drop study : The pressure drop in the
blood chamber was kept from 20 to 40 mmHg. A
high pressure drop was sometimes observed, how-
ever, this was not continuously observed (for only
2 or 3 hours) (Fig. 4). The reason of this high pres-
sure drop was unknown.
CBC and biochemistry study : Table 1 shows the
CBC and blood biochemistry data throughout the
experiment. All the mean values were within nor-
mal limits except for anemia due to bleeding towards
the end of the experiment. Just after the operation,
abnormal levels of WBC, AST and TP were ob-
served, however, they were normalized gradually.
Also, the platelet count was maintained above
200,000/µl.
Visual inspection : After the experiment, the visu-
al inspection of the oxygenator revealed no blood
clot or thrombus formation (Fig. 5).
Necropsy findings : There were no thromboembolic
findings in major organs including liver, kidney,
spleen, intestine, etc. in the macroscopic examina-
tion. However, a huge hematoma in the chest cav-
ity due to the high ACT level was observed.
DISCUSSION
The microporous membrane oxygenator that was
introduced in the early 1960s has been successfully
used for cardiopulmonary bypass during cardiac
surgery. However, plasma leakage through the pores
into the gas phase is one of the limiting factors for
long-term use of these microporous membrane
oxygenators (11-13). The plasma leakage is thought
to be a result of the loss of the hydrophobic char-
acteristics of the micropores by the adsorption of
protein, and that is promoted by an increase in the
outlet blood pressure (14). Several techniques have
been proposed to decrease the plasma leakage, in-
cluding the use of a heated humiditied gas (11, 12,
15), use of high gas flow rate (15), and development
of a more uniform and smaller size porous mem-
brane (16, 17). These techniques require addition-
al complex and expensive devices. In contrast, the
nonporous true membrane oxygenator can com-
pletely prevent plasma leakage without any other
hardware.
ECMO is now a standard treatment for respira-
tory failure refractory to conventional pulmonary
support techniques worldwide, and many patients
are treated with ECMO every year (18). The Kolobow
spiral coil membrane oxygenator (2), the only
ECMO oxygenator approved in the U.S.A., employs
a solid silicone membrane. However, because of
the mechanically weak characteristics of silicone,
manufacturing of hollow fibers from silicone elas-
tomers is difficult and expensive. This author’s
group developed a novel silicone material with suf-
ficient mechanical strength, and a fine silicone hol-
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low fiber with a diameter of 300 µm and wall thick-
ness of 50 µm (3). Utilizing this hollow fiber, an
oxygenator with an improved blood flow distributor
was fabricated. After satisfactory in vitro (8) and
short-term ex vivo (9) performances were achieved, a
2-week ex vivo experiment was successfully performed.
Other groups are also developing high-performance
ECMO oxygenators, for example, Takewa et al.
(19) reported long-term ECMO experiments using
a heparin bonded oxygenator. On the other hand,
our oxygenator was made of silicone rubber with
excellent biocompatibility. This is the first all sili-
cone rubber hollow fiber ECMO oxygenator in the
world.
One of the limitations of conventional silicone
hollow fiber compared with microporous membrane
oxygenators is poor gas permeability. We solved
the problem to some extent by using a novel fine
ultrathin silicone fiber. In this ex vivo experiment,
the O2 and CO2 gas transfer rates were maintained
at the same value of 40 ml/min at a blood flow rate
of 1 L/min flow and V/Q=3 for 2 weeks. Stable and
reliable gas transfer performance under the ECMO
condition is advantageous for long-term usage. How-
ever, O2 and CO2 transfer rates are still limited
comparing the results of in vitro experiments (8).
(A)
(B)
Fig. 2. Gas transfer performance changes
of O2 transfer rate (A) and CO2 transfer
rate (B) for a 2-week ECMO study. Sta-
ble and sufficient gas transfer levels were
revealed. Data are expressed as mean
±SD.
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Further improvements (further increase of the fiber
length and the surface area, etc.) are necessary.
Additionally, the plasma free hemoglobin levels
and pressure drops were within acceptable levels,
and no abnormalities during the blood examination or
necropsy were observed. Excellent biocompatibility
of our silicone membrane oxygenator was proven
in this ex vivo experiment.
The remaining problem is the bleeding compli-
cation due to the anti-coagulant therapy. Because
the preliminary study cases developed oxygenator
occlusion after several days, it was decided that
the ACT level be increased from 200-250 sec to around
400 sec. However, in this study, a huge hematoma
in the chest cavity due to the high ACT level was
observed. During the next ECMO experiment, this
group is proposing the ACT level be in the range of
250-300 sec. These results indicate that this oxygenator
can be used for prolonged ECMO, although further
improvement in thrombo-resistant properties should
be achieved.
In conclusion, a 2-week ex vivo experiment with
the silicone membrane hollow fiber oxygenator was
successfully completed. Stable and reliable perfor-
mance of this oxygenator was proven. These data
demonstrate the feasibility for long-term application
of this newly improved silicone hollow fiber oxygenator.
However, this manuscript is essentially the results
of a single experiment, which confirms the feasi-
bility of our newly-developed oxygenator. It is not
a sufficient number of experiments to confirm the
advantages of our oxygenator. This oxygenator is still
Fig. 3. The change of plasma free hemo-
globin during the 2-week ECMO study.
Fig. 4. The pressure drop in the blood
chamber during the 2-week ECMO study.
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in the development stage, and further experiments
and improvements will be necessary.
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